Literature DB >> 31473181

Clinical outcome after discontinuation of maintenance Electroconvulsive Therapy. A retrospective follow-up study.

Erika Martínez-Amorós1, Pilar Serra2, Ximena Goldberg1, Lara Urraca2, Diego J Palao1, Mikel Urretavizcaya3, Narcís Cardoner4.   

Abstract

INTRODUCTION: Continuation and maintenance electroconvulsive therapy (c/m-ECT) is a therapeutic option after an acute ECT course. Although it is widely used, both duration and the outcome of patients when ECT-c/m is discontinued is not yet well established. The aim of the study was to evaluate the recurrence rate and associated clinical factors when c/m-ECT is discontinued.
MATERIALS AND METHODS: Retrospective evaluation of 73 patients who were discontinued from c/m-ECT. The minimum evaluation time was one year. The need of hospital admission or a new acute course of ECT was considered a relapse. The recurrence rate was calculated as a percentage and the estimated time to recurrence was analyzed through a survival analysis. Possible associations between clinical variables and recurrence were analyzed by univariate and multivariate Cox analysis.
RESULTS: Thirty-six patients (49.3%) relapsed: 61.1% of them relapsed during the first year after the c/m-ECT discontinuation (36.1% during the first 6 months). The estimated time to recurrence was 38.67 months. Fifty percent of patients who relapsed required a new acute course of ECT and 44.4% of them restarted c/m-ECT. Patients with an interval between sessions of less than one month and those with more previous episodes showed a higher risk of recurrence.
CONCLUSIONS: The risk of recurrence should be considered before the discontinuation of c/m-ECT. After the discontinuation, almost half of the patients relapsed, most of them within the first year. Close monitoring should be conducted in these patients and the discontinuation is not recommended when it is administered at intervals between sessions of less than a month. Further studies are required to identify risk groups for relapse.
Copyright © 2019 SEP y SEPB. Publicado por Elsevier España, S.L.U. All rights reserved.

Entities:  

Keywords:  Continuación y mantenimiento; Continuation and maintenance; Electroconvulsive therapy; Recaída; Recidiva; Recurrence; Recurrencia; Relapse; Terapia electroconvulsiva

Mesh:

Year:  2019        PMID: 31473181     DOI: 10.1016/j.rpsm.2019.07.001

Source DB:  PubMed          Journal:  Rev Psiquiatr Salud Ment (Engl Ed)        ISSN: 2173-5050


  6 in total

1.  Discontinuation of maintenance electroconvulsive therapy: Lessons learned from the COVID-19 pandemic.

Authors:  Erika Martínez-Amorós; Pilar Serra; Adriana Bassa; Diego J Palao; Narcís Cardoner
Journal:  Rev Psiquiatr Salud Ment (Engl Ed)       Date:  2022 Apr-Jun

2.  Effectiveness of maintenance electroconvulsive therapy-Evidence from modifications due to the COVID-19 pandemic.

Authors:  Isabel Methfessel; Matthias Besse; Michael Belz; David Zilles-Wegner
Journal:  Acta Psychiatr Scand       Date:  2021-05-18       Impact factor: 7.734

3.  Relapse after abrupt discontinuation of maintenance electroconvulsive therapy during the COVID-19 pandemic.

Authors:  Simon Lambrichts; Kristof Vansteelandt; Bo Crauwels; Jasmien Obbels; Eva Pilato; Jonas Denduyver; Katrien Ernes; Pieter-Paul Maebe; Charlotte Migchels; Lore Roosen; Satya Buggenhout; Filip Bouckaert; Didier Schrijvers; Pascal Sienaert
Journal:  Acta Psychiatr Scand       Date:  2021-06-28       Impact factor: 7.734

4.  Electroconvulsive Therapy During COVID-19-Times: Our Patients Cannot Wait.

Authors:  Pascal Sienaert; Simon Lambrichts; Leen Popleu; Elke Van Gerven; Satya Buggenhout; Filip Bouckaert
Journal:  Am J Geriatr Psychiatry       Date:  2020-04-22       Impact factor: 4.105

5.  Far From an Elective Procedure: Electroconvulsive Therapy and Autism in the Era of COVID-19.

Authors:  Lee Elizabeth Wachtel
Journal:  J ECT       Date:  2021-03-01       Impact factor: 3.692

6.  Maintenance Electroconvulsive Therapy Is an Essential Medical Treatment for Patients With Catatonia: A COVID-19 Related Experience.

Authors:  Neera Ghaziuddin; Tareq Yaqub; Wael Shamseddeen; Priyanka Reddy; Hannah Reynard; Daniel Maixner
Journal:  Front Psychiatry       Date:  2021-07-15       Impact factor: 4.157

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.